Preliminary total global full year 2025 revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year 2025 net product revenue of approximately $182 million and $594 million, respectivelyFull Year 2026 target total global revenue of approximately $875-900 million, including BRIUMVI U.S. net product revenue of approximately $825-850 million NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics), today announced prelimina ...

Five new luxury home collections now available in the highly sought-after Great Park Neighborhoods master planIRVINE, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced its newest Southern California community, Toll Brothers at Great Park Neighborhoods, is now open for sale in Irvine, California. The highly anticipated Sales Center Grand Opening event will take place this Saturday, January 17 from 11 a.m. to 2 p.m. at 153 B ...

PERRYSBURG, Ohio, Jan. 13, 2026 (GLOBE NEWSWIRE) -- O-I Glass, Inc. (NYSE: OI) has scheduled its full year and fourth quarter 2025 conference call and webcast for Wednesday, February 11, 2026, at 8 a.m. EST. The Company’s news release for the full year and fourth quarter 2025 earnings will be issued after the market closes on Tuesday, February 10. What: O-I Conference Call and WebcastEarnings presentation materials will also be posted on the O-I website, www.o-i.com/investors, when the earnings news release ...

- Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well tolerated using a steroid-only prophylactic immunomodulation regimen - - Duchenne: First participant enrolled in IMPACT DUCHENNE, a Phase 3 randomized, double-blind, placebo-controlled, ex-U.S. clinical trial, with dosing expected in Q1 2026 - - FA: First participant dosed in Phase 1b FALCON clinical trial; FDA Orphan Drug designation granted to SGT-212, the only d ...

WEST PALM BEACH, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Solitron Devices, Inc. (OTC Pink: SODI) (“Solitron” or the “Company”) is pleased to announce fiscal 2026 third quarter results. FISCAL 2026 THIRD QUARTER HIGHLIGHTS – Net sales increased 49% to approximately $5.02 million in the fiscal 2026 third quarter versus $3.37 million in the fiscal 2025 third quarter.Net bookings increased 73% to $13.91 million in the fiscal 2026 third quarter versus $8.05 million in the prior year third quarter.Backlog increas ...

ANDOVER, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Mercury Systems Inc. (NASDAQ: MRCY, www.mrcy.com), a global technology company that delivers mission-critical processing to the edge, will release its second quarter fiscal year 2026 financial results after the market close on Tuesday, February 3, 2026. Management will host a conference call and simultaneous webcast at 5:00 p.m. ET on the same day to discuss Mercury's quarterly financial results, business highlights, and outlook. In addition, Company represe ...

LUBBOCK, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) -- South Plains Financial, Inc. (NASDAQ:SPFI) (“South Plains” or the “Company”), the parent company of City Bank, today announced that its fourth quarter 2025 financial results will be released after market close on Monday, January 26, 2026. The Company will host a conference call and webcast at 5:00 p.m. ET on the same day to discuss the financial results. Investors and analysts interested in participating in the call are invited to dial 1-877-407-9716 (intern ...

Fourth quarter 2025 total revenue expected to be approximately $11.3 million, representing growth of approximately 37% compared to the prior-year period.Received record multi-system order in the fourth quarter from an existing Top 20 global biopharma customer to automate global manufacturing network.Full year 2025 total revenue expected to be approximately $33.6 million, representing growth of approximately 20% compared to the prior year. LEXINGTON, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosy ...

SARASOTA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced that it will participate in a webcast fireside chat at the Lytham Partners 2026 Investor Healthcare Summit, taking place virtually on Thursday, January 15, 2026. The webcast will take place at 3:00 p.m. ET on Thursday, January 15, 202 ...

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on January 10, 2026 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of an individual hired by BBOT in December 2025. The employee received non-qualified stock options to purchase 129,090 shares of BBOT common stock, par value $0.0 ...